Dr. Kim Solez Presents "Transition Between Transplant Pathology and Tissue Engineering Pathology: Beginning A New Banff Classification" at the Alberta Transplant Institute Fellows Lecture Series January 10, 2017 at the University of Alberta in Edmonton, Alberta, Canada. Copyright (c) 2017, JustMachines Inc.
Kim Solez - The Future of the Banff Meetings and Banff Foundation for Allogra...Kim Solez ,
Dr. Kim Solez's presentation of The Future of the Banff Meetings and Banff Foundation for Allograft Pathology given at the opening of the Twelve Banff Conference on Allograft Pathology on August 19, 2013, in Comandatuba-Bahia, Brazil. The video of this presentation is at http://youtu.be/Hctwcq7FHvE See http://cybernephrology.ualberta.ca/banff/2013
Kim Solez Transplant Pathology Regen Med 2015Kim Solez ,
Dr. Kim Solez presents Transplantation Pathology, Regenerative Medicine, and Where We Go From Here at the Nephrology Core Lecture Series on January 7th, 2015 at the University of Alberta in Edmonton, Canada. See https://www.youtube.com/watch?v=5wfdhB_VyJw
Presentation for industry of plans for the 2015 Banff/CST joint meeting in Vancouver BC Oct. 5-10, 2015, a preview given at the World Transplant Congress in San Francisco on July 27, 2014 by Drs. Kim Solez, Michael Mengel, and John Gill.
Transition transplant path to tissue engineer path new banff class 2017 Kim Solez ,
Kim Solez "The transition between transplant pathology and tissue engineering pathology: Beginning a new Banff classification - 2017 Update". ATI Fellows Rounds Presentation Spept 12 2017
Kim Solez AI opportunities for students in 2017Kim Solez ,
The Future and All That Jazz Kim Solez AI opportunities for students in 2017 Lecture introduction January 24, 2017. Copyright (c) 2017, JustMachines Inc.
Kim Solez - The Future of the Banff Meetings and Banff Foundation for Allogra...Kim Solez ,
Dr. Kim Solez's presentation of The Future of the Banff Meetings and Banff Foundation for Allograft Pathology given at the opening of the Twelve Banff Conference on Allograft Pathology on August 19, 2013, in Comandatuba-Bahia, Brazil. The video of this presentation is at http://youtu.be/Hctwcq7FHvE See http://cybernephrology.ualberta.ca/banff/2013
Kim Solez Transplant Pathology Regen Med 2015Kim Solez ,
Dr. Kim Solez presents Transplantation Pathology, Regenerative Medicine, and Where We Go From Here at the Nephrology Core Lecture Series on January 7th, 2015 at the University of Alberta in Edmonton, Canada. See https://www.youtube.com/watch?v=5wfdhB_VyJw
Presentation for industry of plans for the 2015 Banff/CST joint meeting in Vancouver BC Oct. 5-10, 2015, a preview given at the World Transplant Congress in San Francisco on July 27, 2014 by Drs. Kim Solez, Michael Mengel, and John Gill.
Transition transplant path to tissue engineer path new banff class 2017 Kim Solez ,
Kim Solez "The transition between transplant pathology and tissue engineering pathology: Beginning a new Banff classification - 2017 Update". ATI Fellows Rounds Presentation Spept 12 2017
Kim Solez AI opportunities for students in 2017Kim Solez ,
The Future and All That Jazz Kim Solez AI opportunities for students in 2017 Lecture introduction January 24, 2017. Copyright (c) 2017, JustMachines Inc.
Kim Solez Charles dickens and transplant pathologyKim Solez ,
Acceptance speech by Dr. Kim Solez receiving the Catalan Society of Transplantation Gold Medal on behalf of himself and Dr. Lorraine Racusen March 31, 2017
Kim Solez Renal transplant pathology and future perspectivesKim Solez ,
Dr. Kim Solez presents "Renal transplant pathology and future perspectives" as a TTS webinar on Dec. 8 at noon EST . Includes discussion of the new discipline of tissue engineering pathology. https://www.tts.org/education/advanced-renal-transplantation
Kim Solez Regenerative Medicine II when the wild west period will endKim Solez ,
Dr. Kim Solez presents "Regenerative Medicine Part II: When Will the Current "Wild West" Period End and What Should We Do in the Meantime? on March 2nd, 2017 in the Technology and Future of Medicine course LABMP 590 at the University of Alberta in Edmonton, Alberta, Canada. Copyright (c) 2017, JustMachines Inc.
Kim Solez TEP meets Human Cell Atlas a glimpse into future of pathology winte...Kim Solez ,
Dr. Kim Solez TEP meets Human Cell Atlas Project, a glimpse into future of pathology, Technology and Future of Medicine course February 15, 2018 http://www.singularitycourse.com Copyright (c) 2018, JustMachines Inc.
Kim Solez Bridge between transplantation and regenerative medicine vancouver3Kim Solez ,
Dr. Kim Solez presents "Bridge between Transplantation and Regenerative Medicine" at the Banff Transplant Pathology meeting in Vancouver October 5, 2015. Copyright (c) 2015, JustMachines Inc.
Kim Solez Introduction to regenerative medicine Fall 2015Kim Solez ,
Dr. Kim Solez presents "Introduction to Regenerative Medicine" on September 10, 2015 in the Technology and Future of Medicine course LABMP 590 http://www.singularitycourse.com at the University of Alberta in Edmonton, Canada. Copyright (c) 2015, JustMachines Inc.
Solez Stem Cell and Future of TransplantationKim Solez ,
Dr. Kim Solez discusses "Confronting the Question of Stem Cells and the Future of Transplantation" for the Alberta Transplant Institute Fellows Lecture Series on September 2nd, 2014 at the University of Alberta in Edmonton, Canada.
Kim Solez The bridge between transplant and regenerative med Tissue engineeri...Kim Solez ,
Dr. Kim Solez presents "The Bridge Between Transplantation & Regenerative Medicine: The Beginning of Tissue Engineering Pathology" at the ATI Fellows Lecture Series on August 18, 2015.
Kim Solez Tissue Engineering Pathology Meets Human Cell Atlas a Glimpse into ...Kim Solez ,
Dr. Kim Solez presents "Tissue Engineering Pathology Meets Aviv Regev's Human Cell Atlas: A Glimpse Into the Future of Pathology" on March 8th, 2017 at the University of Alberta in Edmonton, Alberta, Canada Copyright (c) 2017, JustMachines Inc.
Kim Solez A renaissance in renal pathology brought about by regenerative medi...Kim Solez ,
Dr. Kim Solez presents A renaissance in renal pathology, nephrology and transplantation brought about by regenerative medicine: How to jump start the process.
Kim Solez Xenotransplantation- The Rest of the Story April 8 2022 6.pptxKim Solez ,
Nephrology Grand Rounds Presentation at the University of Alberta discussing the big picture issues surrounding xenotransplantation and its relation to stem cell generated organs and bioengineered organs in the future
Solez Update on the Technology and Future of Medicine Course: Space, Regenera...Kim Solez ,
Dr. Kim Solez presents Update on the "Technology and Future of Medicine Course: Space, Regenerative Medicine, Large Touch Screens, and Leonard Cohen" on September 25, 2014 at Lab Medicine Pathology Grand Rounds at the University of Alberta in Edmonton, Canada.
Kim Solez Renal transplant pathology and future perspectives corefall2016Kim Solez ,
Dr. Kim Solez presents "Renal transplant pathology and future perspectives. Nephrology core lecture series Fall 2016, on October 5, 2016, at the University of Alberta, Edmonton, Alberta, Canada. Copyright (c) 2016, JustMachines Inc.
Ishita Moghe Kim Solez Human cell atlas paradox and what you can do to promot...Kim Solez ,
Ishita Moghe Kim Solez Human cell atlas paradox and what you can do to promote it in context of world future 2018 human purpose. Slide set for Future Day presentation March 1st, 2018. Copyright (c) 2018, JustMachines Inc.
Kim Solez Charles dickens and transplant pathologyKim Solez ,
Acceptance speech by Dr. Kim Solez receiving the Catalan Society of Transplantation Gold Medal on behalf of himself and Dr. Lorraine Racusen March 31, 2017
Kim Solez Renal transplant pathology and future perspectivesKim Solez ,
Dr. Kim Solez presents "Renal transplant pathology and future perspectives" as a TTS webinar on Dec. 8 at noon EST . Includes discussion of the new discipline of tissue engineering pathology. https://www.tts.org/education/advanced-renal-transplantation
Kim Solez Regenerative Medicine II when the wild west period will endKim Solez ,
Dr. Kim Solez presents "Regenerative Medicine Part II: When Will the Current "Wild West" Period End and What Should We Do in the Meantime? on March 2nd, 2017 in the Technology and Future of Medicine course LABMP 590 at the University of Alberta in Edmonton, Alberta, Canada. Copyright (c) 2017, JustMachines Inc.
Kim Solez TEP meets Human Cell Atlas a glimpse into future of pathology winte...Kim Solez ,
Dr. Kim Solez TEP meets Human Cell Atlas Project, a glimpse into future of pathology, Technology and Future of Medicine course February 15, 2018 http://www.singularitycourse.com Copyright (c) 2018, JustMachines Inc.
Kim Solez Bridge between transplantation and regenerative medicine vancouver3Kim Solez ,
Dr. Kim Solez presents "Bridge between Transplantation and Regenerative Medicine" at the Banff Transplant Pathology meeting in Vancouver October 5, 2015. Copyright (c) 2015, JustMachines Inc.
Kim Solez Introduction to regenerative medicine Fall 2015Kim Solez ,
Dr. Kim Solez presents "Introduction to Regenerative Medicine" on September 10, 2015 in the Technology and Future of Medicine course LABMP 590 http://www.singularitycourse.com at the University of Alberta in Edmonton, Canada. Copyright (c) 2015, JustMachines Inc.
Solez Stem Cell and Future of TransplantationKim Solez ,
Dr. Kim Solez discusses "Confronting the Question of Stem Cells and the Future of Transplantation" for the Alberta Transplant Institute Fellows Lecture Series on September 2nd, 2014 at the University of Alberta in Edmonton, Canada.
Kim Solez The bridge between transplant and regenerative med Tissue engineeri...Kim Solez ,
Dr. Kim Solez presents "The Bridge Between Transplantation & Regenerative Medicine: The Beginning of Tissue Engineering Pathology" at the ATI Fellows Lecture Series on August 18, 2015.
Kim Solez Tissue Engineering Pathology Meets Human Cell Atlas a Glimpse into ...Kim Solez ,
Dr. Kim Solez presents "Tissue Engineering Pathology Meets Aviv Regev's Human Cell Atlas: A Glimpse Into the Future of Pathology" on March 8th, 2017 at the University of Alberta in Edmonton, Alberta, Canada Copyright (c) 2017, JustMachines Inc.
Kim Solez A renaissance in renal pathology brought about by regenerative medi...Kim Solez ,
Dr. Kim Solez presents A renaissance in renal pathology, nephrology and transplantation brought about by regenerative medicine: How to jump start the process.
Kim Solez Xenotransplantation- The Rest of the Story April 8 2022 6.pptxKim Solez ,
Nephrology Grand Rounds Presentation at the University of Alberta discussing the big picture issues surrounding xenotransplantation and its relation to stem cell generated organs and bioengineered organs in the future
Solez Update on the Technology and Future of Medicine Course: Space, Regenera...Kim Solez ,
Dr. Kim Solez presents Update on the "Technology and Future of Medicine Course: Space, Regenerative Medicine, Large Touch Screens, and Leonard Cohen" on September 25, 2014 at Lab Medicine Pathology Grand Rounds at the University of Alberta in Edmonton, Canada.
Kim Solez Renal transplant pathology and future perspectives corefall2016Kim Solez ,
Dr. Kim Solez presents "Renal transplant pathology and future perspectives. Nephrology core lecture series Fall 2016, on October 5, 2016, at the University of Alberta, Edmonton, Alberta, Canada. Copyright (c) 2016, JustMachines Inc.
Ishita Moghe Kim Solez Human cell atlas paradox and what you can do to promot...Kim Solez ,
Ishita Moghe Kim Solez Human cell atlas paradox and what you can do to promote it in context of world future 2018 human purpose. Slide set for Future Day presentation March 1st, 2018. Copyright (c) 2018, JustMachines Inc.
Stem-cell therapy in medicine–how far we came and what we can expect?Apollo Hospitals
The name ‘stem-cell’ is making the news in recent times both for good and not. The current articles tries to give a snap shot of the scientific and clinical picture of stem-cells in medicine as of today and discuss what it have to offer in the to the mankind. The article discusses the characters and types of stem-cells, their current indication in therapeutics (both established and upcoming), as well as their use in research. It also gives a brief overview of the current laws guiding its use in clinical practice and the various cultural beliefs associated with the use of same.
Slide deck for annual meeting of Transplant Regenerative medicine Community of Practice of American Society of Transplantation at noon in Room 204 in John B. Hynes Convention Center. Everyone welcome! Many exciting initiatives to discuss!
Kim Solez Hooking-Up Physical Forces Optimism and Dark Energy Presentation Se...Kim Solez ,
Kim Solez Banff New Media Institute Presentation, "Smart, Sexy, Healthy" ThinkTank, Sept 6 2001
Hooking-Up, Physical Forces, Optimism and Dark Energy: Imagery, Hope, and Health.
Kim Solez 384 years of banff spirit new june 26 2019Kim Solez ,
Kim Solez 384 years of Banff spirit new June 26 2019 The most remarkable slide is number 137. "By Spring of 2019 every erroneous statement we complained about had been reversed. We celebrated by creating a new video trailer on our YouTube channel on June 25 2019." How about that!
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
4. Worldwide 1.2 million people are in
need of transplantation for end
stage organ failure. Current
transplant protocols reach fewer
than 10% of this number.
Regenerative medicine can save the
remaining 90%, over one million
people annually!
5. Tissue engineered bladder.
Regenerative Medicine Already Here!
Working for Tubular Organs, Bladder,
Trachea, Esophagus, Vagina.
7. ViaCyte Announces Highly
Anticipated Encapsulation Clinical
Trial Site Expansion into Canada
JDRF-funded researcher, Dr. James Shapiro
will be the lead investigator at the Canadian
site. TORONTO, July 29, 2015 -- ViaCyte, Inc.
announced the opening of a second site in its
Phase 1/2 trial for Type I Diabetes which utilizes
PEC-01™ pancreatic progenitor cells and the
proprietary Encaptra® drug delivery system which
is designed to protect the transplanted cells from a
patient’s immune system.
Regenerative Medicine Already Here!
Viacyte Trial for Diabetes Therapy.
8. Double Think: Stem Cells are Greatest Hope
and Greatest Hype, Stem Cell Tourism
Estimated to be $3 Billion a Year Industry and
Growing, with More than 700 Clinics Worldwide
Mason C et al. Regen Med. 2011 May;6(3):265-72. doi:
10.2217/rme.11.28. Cell therapy industry: billion dollar
global business with unlimited potential.
Timothy Caulfield - Stem Cell Tourism June 2015
https://www.youtube.com/watch?v=B0r89nMtg10
9. University of Alberta Health Law Institute
http://www.hli.ualberta.ca/en/Publications.as
px Stem cell Publications
Science, Celebrities, and Public Engagement Timothy
Caulfield and Declan Fahy on Science, Celebrities, and
Public Engagement in the Summer 2016 Issues in Science
and Technology. www.issues.org JUNE 16, 2016
Science: Confronting stem cell hype Professor
Timothy Caulfield co-authors new stem cell policy
guidelines. MAY 13, 2016
10. University of Alberta Health Law Institute
http://www.hli.ualberta.ca/en/Publications.as
px Stem cell Publications
Science: Confronting stem cell hype Professor
Timothy Caulfield co-authors new stem cell policy
guidelines. MAY 13, 2016
Stem cell hype: Media portrayal of therapy
translation MARCH 30, 2015
Policy Options: Athletes and unproven stem cell
therapies JANUARY 01, 2015
11. University of Alberta Health Law Institute
http://www.hli.ualberta.ca/en/Publications.aspx
Stem cell publications continued
Research ethics and stem cells Is it time to re‐think
current approaches to oversight? DECEMBER 04, 2014
Representations of Stem Cell Clinics on
Twitter DECEMBER 01, 2014
Unproven stem cell-based interventions & physicians'
professional obligations; a qualitative study with
medical regulatory authorities in Canada. OCTOBER 14,
2014 Professional Regulation: A Potentially Valuable
Tool in Responding to "Stem Cell
Tourism" SEPTEMBER 09, 2014
12. University of Alberta Health Law Institute
http://www.hli.ualberta.ca/en/Publications.aspx
Stem cell publications continued
Stem Cell Tourism and Public Education: The Missing
Elements SEPTEMBER 04, 2014
Policy recommendations for addressing privacy
challenges associated with cell-based research and
interventions FEBRUARY 03, 2014 Commercialization
and Stem Cell Research: A Review of Emerging Issues
DECEMBER 20, 2013 A Role for Patient Advocacy
Groups in Countering the Premature Commercialization
of Stem Cell Interventions
OCTOBER 01, 2013
13. The Positive Aspects of Stem Cell Therapies,
The True Hope, Has Potential to Reverse Three
Looming Problems in Medicine:
1. The loss of “luster” in transplantation.
2. Workforce problems in nephrology due to lack of appeal
to young people/potential trainees worldwide.
3. Technological unemployment in medicine due to
14. “They will never be able to reverse those
trends.” Together we can do those things,
reverse those trends, make life good again!
1. The loss of “luster” in transplantation.
2. Workforce problems in nephrology due to lack of appeal
to young people/potential trainees worldwide.
3. Technological unemployment in medicine due to
16. Banff Classification of Kidney Transplant Pathology
Histologic criteria for the diagnosis of rejection and
other conditions in the transplanted kidney, began
1991, updated and expanded every two years in
consensus meeting.
17. Banff Lesion Scoring: Sign of Educated Tx Pathologist
imprimatur 1. The formula (=‘let it be printed’), signed by an official
authorizing printing of a book;hence as sb. an official license to print.
The Oxford English Dictionary (2nd. ed.)
Banff lesion scoring: g cg i ci t ct v cv ah mm ptc C4d
18. 1991 First Conference
1993 First Kidney International publication
1995 Integration with CADI
1997 Integration with CCTT classification
1999 Second KI paper. Clinical practice guidelines. Implantation biopsies.
2001 Classification of antibody-mediated rejection: Regulatory agencies
participating
2003 Genomics focus, ptc cell accumulation scoring
2005 Gene chip analysis. Elimination of CAN, identification of chronic
antibody-mediated rejection.
2007 First meeting far from a town called “Banff” – La Coruna, Spain.
2009 Working groups. Meeting in Banff, Alberta, Canada
2013 Establishment of Banff Foundation for Allograft Pathology
19. Significance of ‘Banff papers’
• More than 5,000 citations of the 14 Banff meeting reports
• 977 Banff / Transplantation papers in PubMed
• Banff 2003 meeting report (ABMR criteria) = most cited AJT
paper
• 3 Banff meeting reports are among the top 4 cited AJT articles
21. The Banff Process
Consensus communication in renal transplantation
a
The Banff
lesions
g, i, t, v - score
The Banff
community
Pathologists
Nephrologists
Tx-Surgeons
Lab-Medicine
established by
consensus in 1991
The Banff
classification
Current consensus for
diagnostics
moderated
Banff meetings
thesis-antithesis-synthesis
tentative
thresholds
participate
refinementBanff Working
Groups
Feedback concerning weaknesses and strengths by results
from independent research
New members
Biostaticians
Molecular Biologists
“Omics”-specialists
Off-springs
Liver
Pancreas
Lung, Heart
CTA
22. Organizational structure of the Banff Foundation For Allograft Pathology
Board of Trustees:
K. Solez (Chair), L. Racusen, D. Glotz, J. Demetris, M. Mengel, M. Mihatsch, D. Seron
2015 Local Conference
chair: Michael Mengel
Organ Steering committee
Chairs:
Composite tissues: Linda Cendales
Heart : Patrick Bruneval
Kidney: Mark Haas
Liver: Jake Demetris
Lung: William Wallace and Carol
Farver
Pancreas: Cinthia Drachenberg
Banff Working Group (BWG) Leads:
Molecular transplantation pathology: Michael Mengel, Banu Sis
Isolated v-lesions: Banu Sis, Ed Kraus
Quality assurance in transplantation diagnostics: Michael Mengel and
Parmjeet Randhawa
C4d-negative ABMR: Mark Haas, Banu Sis, Alexandre Loupy
Fibrosis scoring: Robert Colvin, Brad Farris, Michael Mengel
Digital Pathology in Transplantation: Jake Demetris
2015 Scientific program committee:
Alex Loupy (Chair)
Mark Haas, Banu Sis, Kathryn Tinkham, Candice
Rofousse, Chris Bellamy, Lynn Cornell, Carmen
LeFaucheur
Composite tissues: Linda Cendales
Heart : Patrick Bruneval
Liver: Jake Demetris
Lung: William Wallace and Carol Farver
Pancreas/Islets: Cinthia Drachenberg and John
Papadimitriou
Secretary/Treasurer:
Michael Mengel
funding
collaboration
reports to
reports to
collaboration
collaboration
reports to
collaboration
progress
reports to Budged
proposal and
accountability
for meeting
costs
support
33. Many problems with stem cell generate
organs not being discussed. Do not exclude
yourself from the action in this area!
34. Many problems with stem cell generate
organs not being discussed. Need to get
those conversations to happen.
The recellularized organ clots like crazy, impossible to
regenerate more than 80% of endothelial surface. Artificial
heparized surface not fenestrated. Cell traffic abnormal.
Hard to get right types of cells to right places.
Podocytes seems to be terminally differentiated cells,
when attempt to culture them they turn into different type of
cell.
Kidney progenitor stem cell difficult to identify, kidney work
has lagged behind.
Easy to make stem cell generated kidneys that lack loop of
Henle. Could produce lethal polyuria. What is “function”?
Many old fashioned questions of physiology about how the
stem cell generated organ works, not just true for kidney,
true for every organ.
35. Transplant
pathologists will also
become tissue
engineering
pathologists,
pathologists who
analyse organs grown
from stem cells. This is
not something beyond
us, we can adapt to a
work life that includes
stem cells.. Someone
needs to cross the
disciplines,
36. Many of the questions
that need to be posed
about stem cell
generated organs are old
fashioned questions,
intact nephron
hypothesis, cell
regeneration, stunned
myocardium, contraction
band necrosis etc. Use
your nostalgia! Stimulate
conversations between
stem cell researchers and
transplant physicians.
37. Beginning at the Very Beginning!
“We are at the very beginning of time for the human race. It
is not unreasonable that we grapple with problems. But
there are tens of thousands of years in the future. Our
responsibility is to do what we can, learn what we can,
improve the solutions, and pass them on.” - Richard P.
Feynman, (1918-1988) Physicist, Nobel Prize Winner
"The sense of the future is behind all good policies. Unless
we have it, we can give nothing either wise or decent to
the world." - Snow CP, (1905-1980) Novelist and
Philosopher.
"To a large extent, the future lies before us like a vast
wilderness of unexplored reality. The God who created and
sustained the evolving universe through eons of progress
and development has not placed our generation at the tag
end of the creative process. God has placed us at a new
beginning. We are here for the future." - Sir John
Templeton (1912-2008 ), Financial Analyst
38. Beginning at the Very Beginning!
Like 1851 when the first International Classification of
Diseases was presented in the Grand Exhibition of
Technology at London’s Crystal Palace
Emphasis was on cause of death
39. Classification focus is on sustaining life.
Native and transplanted organ diseases can also occur in
tissue engineered organs.
The classification focus of the new pathology discipline of
Regenerative Medicine/Tissue Engineering Pathology is
exactly the opposite of traditional classification of disease
which starts with causes of death. In Regenerative
Medicine/Tissue Engineering Pathology the emphasis is on
the degree of normality necessary to sustain life:
Normal,
Abnormalities of unknown functional significance,
Abnormalities which will impair the main functions of the
organ,
Abnormalities leading to severe organ dysfunction where
function may not be great enough to sustain life.
40. Song et al. Interstitium, vessels, and glomeruli with missing cells.
Disordered tubule formation with multiple interconnecting
lumina of differing sizes. “Can you really call this a kidney?” (Yes!)
41. Song et al. In addition to missing cells and disordered structures,
you have cells in the wrong places. Podocytes in the interstitium.
42. Focus of Tissue Engineering Pathology
The focus of tissue engineering pathology will shift to
the question: “Is this organ structurally intact enough to
function safely and adequately in the recipient?” Using
the kidney as an example, the specific questions
become: (Images by Korey Fung)
1. Are there too many missing cells, distorted
structures for the organ to function adequately?
43. Focus of Tissue Engineering Pathology
The focus of tissue engineering pathology will shift to
the question: “Is this organ structurally intact enough to
function safely and adequately in the recipient?” Using
the kidney as an example, the specific questions
become: (Images by Korey Fung)
2. Are there too many cells in the wrong places (e.g.
podocytes in the interstitium)
44. Focus of Tissue Engineering Pathology
(Images by Korey Fung)
3. Are there missing/distorted structural elements that
represent a risk to the patient? (missing loops of Henle
causing lethal polyuria)
45. Focus of Tissue Engineering Pathology
Using the kidney as an example, the specific questions
become:
4. Is there too much endothelial disruption
for the organ to be properly perfused?
5. What are the risks of neoplastic transformation?
Classification categories should be not one-off, but
reproducible, generalizable.
Tissue engineering pathology has been up to now
really dull, since most reports were of scaffolds with no
inflammatory reaction "Move along, nothing to see
here" pathology, but from today becomes really
exciting with novel morphological changes and lives
hanging in the balance!
46. Khouloud Saliba and I Presented These Ideas
at TERMIS (Regenerative Medicine) Meeting
in San Diego Dec. 11-14, 2016.
47. Met Astgik Petrosyan Who Has Written About
the Many Additional Variables Which Will
Add Complexity to New Banff Classification
Decellularized Renal Matrix and Regenerative
Medicine of the Kidney: A Different Point of
View Petrosyan Astgik, … and Perin Laura. Tissue
Engineering Part B: Reviews. May 2016, 22(3): 183-
192.
A Step Towards Clinical Application
of Acellular Matrix: A Clue from Macrophage
Polarization. Petrosyan A, …Perin L. Matrix Biol. 2016
Aug 26. pii: S0945-053X(16)30133-0.